Over the last several months, IQVIA and Polaris have been surveying our US clients to identify trends in the compliance landscape, and learning more about how Life Sciences companies are evolving their compliance programs, adapting to increased regulatory requirements and taking a more proactive approach to compliance risk management.
The survey results, comprised of answers from respondents from pharmaceutical and medical device companies, touch on these key trends:
- Due to stability in reporting, more companies are dedicating additional time and resources to using transparency data for business and compliance insights.
- Companies are continuing to invest in systems and processes that manage “upstream” relationships with healthcare providers and consultants, recognizing that the greater compliance risks center around these relationships than on the reported spend itself.
- Companies have continued the trend of outsourcing some or all of their existing transparency operations as a way to reduce costs internally.